Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aminolevulinic acid - DUSA

Drug Profile

Aminolevulinic acid - DUSA

Alternative Names: 5 ALA; 5-Aminolaevulinic acid; 5-Aminolevulinic acid; ALA - DUSA; aminolevulinic acid HCL - DUSA; Delta-aminolevulinic acid; Levulan PDT; Levulan photodynamic therapy; Levulan/Kerastick; Levulan™

Latest Information Update: 21 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PARTEQ Innovations
  • Developer Cleveland Clinic; DUSA Pharmaceuticals
  • Class Amino acids; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Antioxidants; Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal dysplasia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Actinic keratosis
  • Phase II Basal cell nevus syndrome; Brain cancer; Skin cancer
  • Suspended Warts
  • No development reported Barrett's oesophagus
  • Discontinued Acne vulgaris; Leucoplakia; Oesophageal cancer; Photodamage; Psoriasis

Most Recent Events

  • 26 Dec 2018 DUSA filed a motion for preliminary injunctive relief regarding the patent dispute between DUSA and Biofrontera
  • 24 Jul 2018 DUSA Pharmaceuticals files lawsuit againts Biofrontera for patent infringement, trade secret misappropriation and tortious interferance claims for aminolevulinic acid HCl in the US
  • 03 Nov 2017 DUSA Pharmaceuticals withdraws a phase III trial for Actinic keratosis prior to enrolment in USA due to corporate business decision (Topical) (NCT03024060)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top